CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
Trial Parameters
Brief Summary
A prospective imaging and translational tissue study in CNS lymphoma to enable further disease characterisation and the development of potential predictive and prognostic biomarkers.
Eligibility Criteria
Inclusion Criteria: * Subjects capable of giving informed consent, or if appropriate, if subject's capacity is deemed limited due to CNS involvement, a consultee can provide consent on their behalf. Some patients with PCNSL may be incapable of providing their own consent due to the neurological effects of their disease. In these cases the patient will be classed as an incapacitated adult and a legal representative will be sought in accordance with English or Scottish law as applicable (see 7.2.1) * A radiological or histological diagnosis of primary CNS lymphoma. * Have not received prior CNS directed therapy. Prior use of steroids is permitted. * Participants aged ≥18 years old. Exclusion Criteria: \- Involvement of lymphoma outside of the CNS